Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。

サイズ 価格(税別) 在庫  
JPY 25730.00 あり
JPY 14940.00 あり
JPY 28220.00 あり
JPY 53120.00 あり
JPY 94620.00 あり

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NG\LO3pHfW6ldHnvckBCe3OjeR?= M4eyOFAvPcLizszN M3PJdlI1KGh? M3XsUpdifGW{ M3OzT41w\HWuYYTld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIF3BS2UuSSCvZX3i[ZJ{ NFTrRnYzPTF{M{C4Ni=>
Eca109 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPrNE42NzJwNT:1JO69VQ>? NYi2TGVIOjRxNEivO|IhcA>? M4ewUpdifGW{ NGP3VZhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NEDKOHEzPTF{M{C4Ni=>
Eca109 M3;4O2Z2dmO2aX;uJGF{e2G7 NXvUe2I1OC53wrFOwG0> NIDIXlI3NzF{L{K0JIg> NUO4dY93f2G2ZYK= NWn5cZM3cW6qaXLpeJMh[2WubDDtbYdz[XSrb39CpC=> M33qO|I2OTJ|MEiy
Eca109 NFrVcmRHfW6ldHnvckBCe3OjeR?= NVnTOlBEOC53wrFOwG0> MYOyOEBp NHHSd2N4[XSnch?= MUXpcohq[mm2czDj[YxtKGmwdnHzbY9v MWGyOVEzOzB6Mh?=
Eca109 NWLtd|BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTOfWg2OC53wrFOwG0> NXHkb45xOjRiaB?= NIjURYR4[XSnch?= MUnpcoR2[2W|IFeyM20h[XK{ZYP0JIlvKHSqZTDj[YxtKGO7Y3zl NF[2cHkzPTF{M{C4Ni=>
Eca109 NWjsZm9vTnWwY4Tpc44hSXO|YYm= NEi3[JAxNjVxMTFOwG0> MkXvNlQhcA>? NYeyXoRsf2G2ZYK= NYnWSHN1\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= M1PP[VI2OTJ|MEiy
SW1116  NV7V[2p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT0OmJxOC53L{GvNk82KM7:TR?= MVK0PEBp M2jjT2ROW09? Mn3Z[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NULwOmJ2OjR6N{SyPFY>
LOVO Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHR[WQxNjVxMT:yM|Uh|ryP NWfSN2xjPDhiaB?= NHTIZWRFVVOR NWezXGxn\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? NVzSdXh5OjR6N{SyPFY>
SW1116  NWfxbFFyTnWwY4Tpc44hSXO|YYm= MVSxNEDPxE1? MXe0PEBp MVTEUXNQ MnLLbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj NHjhOG4zPDh5NEK4Oi=>
LOVO MYfGeY5kfGmxbjDBd5NigQ>? MXqxNEDPxE1? MYC0PEBp NITzV2VFVVOR NFHsPFhqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? M33vdFI1QDd2Mki2
SW1116  NI\ZfVdCeG:ydH;zbZMhSXO|YYm= MUmxNEDPxE1? NUXIeYhvPDhiaB?= M{LU[2ROW09? NH3XTFFmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> MV[yOFg4PDJ6Nh?=
LOVO NYP4XW81SXCxcITvd4l{KEG|c3H5 MoTXNVAh|ryP M3vxbFQ5KGh? NYfVfGhUTE2VTx?= M3f6OoVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> Mk\tNlQ5PzR{OE[=
RPMI-8226 NH\0XpJCeG:ydH;zbZMhSXO|YYm= NGf5UmIyNzJizszN Mn7COFgwPzJxOU[gbC=> MnfpSG1UVw>? NY\jW4xncW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWrzTmhXOjR6M{OxNFg>
OPM-2  MWTBdI9xfG:|aYOgRZN{[Xl? MWexM|Ih|ryP MmT2O|IwQTZxMUKwJIg> M3Hye2ROW09? M{LoWIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2PWVlI1QDN|MUC4
JJN3  NUTCfG1vSXCxcITvd4l{KEG|c3H5 NVyzTVRtOC53L{Gg{txO NIfoNGozPC92ODDo NVXVelU2TE2VTx?= MXTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYHqcVdIOjR6M{OxNFg>
NCI-H929  MV\BdI9xfG:|aYOgRZN{[Xl? M13nWFEwOiEQvF2= NWjwOXdbPzJxOU[vNVIxKGh? NGXFWHhFVVOR MnXBbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NXX3fWtVOjR6M{OxNFg>
RPMI-8226 M3H5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP2NU8zKM7:TR?= Mor0NlQwPDhxN{KgbC=> Mom3SG1UVw>? NH\YOHVi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MlvyNlQ5OzNzMEi=
OPM-2  MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxM|Ih|ryP MmHsNlQwPDhxN{KgbC=> NV7id|h5TE2VTx?= M4XhdYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MoC4NlQ5OzNzMEi=
JJN3  NVXmWoQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjv[VlWOC53L{Gg{txO Mn[yNlQwPDhxN{KgbC=> NWL4WotMTE2VTx?= NF[1VZBi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MWOyOFg{OzFyOB?=
NCI-H929  NYGzRW15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLiNU8zKM7:TR?= MYeyOE81QC95MjDo M2\6PGROW09? Mly1ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MVSyOFg{OzFyOB?=
HeLa MnSwT4lv[XOnIFHzd4F6 M17KfWtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> MUWyOFc5ODB7OB?=
HeLa Ml7CT4lv[XOnIFHzd4F6 NYLHbGRrU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz MUmyOFc5ODB7OB?=
HeLa MmLsT4lv[XOnIFHzd4F6 MlnkT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> Moj1NlQ4QDByOUi=
HeLa MmHIT4lv[XOnIFHzd4F6 Mmm0T4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> MXqyOFc5ODB7OB?=
NB4 M3nibGZ2dmO2aX;uJGF{e2G7 NY\nd5Y3Oi53L{WvO{42NzFyIN88US=> Ml3WNlQhcA>? MnnvSG1UVw>? MVfpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh MVWyOFQ5PDh5MB?=
CD4+ CD25− T  M2L0fGZ2dmO2aX;uJGF{e2G7 M4DIW|EwPSEQvF2= M4XnPZJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? MWWyOFQ4PjN4MB?=
BV-173 MXjBdI9xfG:|aYOgRZN{[Xl? NHXXW4QxNjJ3L{CuOU8xNjd3L{Gg{txO NH7zZoI1QC95Mj:5OkBp NUHDc4RGyqCSQmO= Mn;nbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NXLzOpV7OjR2MkO2NVM>
ML-1 NHv2WGFCeG:ydH;zbZMhSXO|YYm= NGXwb2sxNjJ3L{CuOU8xNjd3L{Gg{txO MnjiOFgwPzJxOU[gbC=> MkH3xsBRSlN? NVrMUmE2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz Mo[xNlQ1OjN4MUO=
HL-60 Mnq3RZBweHSxc3nzJGF{e2G7 NVrJfZlMOC5{NT:wMlUwOC55NT:xJO69VQ>? M3PFSlQ5Nzd{L{m2JIg> MYJCpHBDWw>? NVL5R5FDcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M3KwTFI1PDJ|NkGz
KG-1a MX\BdI9xfG:|aYOgRZN{[Xl? NUnvfY9bOC5{NT:wMlUwOC55NT:xJO69VQ>? NIrzfoI1QC95Mj:5OkBp MURCpHBDWw>? M{n2OYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NEnHeWwzPDR{M{[xNy=>
BV-173 M3e1e2Z2dmO2aX;uJGF{e2G7 NIrBO4wzPTBxNUCwcm0> NHLZc|E1QCCq MlLvxsBRSlN? MmnqbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MmH0NlQ1OjN4MUO=
CEM NYPKWHk4TnWwY4Tpc44hSXO|YYm= Mlj4NlUxNzVyMH7N MnfzOFghcA>? NVG2blI2yqCSQmO= NXHJSmtWcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MVWyOFQzOzZzMx?=
HL-60 MVLGeY5kfGmxbjDBd5NigQ>? NEH2b|UzPTBxNUCwcm0> M3PMN|Q5KGh? MXZCpHBDWw>? MY\pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MlnvNlQ1OjN4MUO=
ML-1 M4iyc2Z2dmO2aX;uJGF{e2G7 MlrrNlUxNzVyMH7N NVLKN2pUPDhiaB?= M1;ZNeKhWEKV NITV[I5qdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NH:zWJQzPDR{M{[xNy=>
DLD-1 NHe3bWZHfW6ldHnvckBCe3OjeR?= MkPENlUxNzVyMH7N MVW0PEBp NWrMTpFUyqCSQmO= Mn21[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? M{G2dlI1PDJ|NkGz
HCT-116 NGfROGRHfW6ldHnvckBCe3OjeR?= M2KzOVI2OC93MEDuUS=> MmDlOFghcA>? NH3GRWPDqFCEUx?= NHvqXpZldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M{TkR|I1PDJ|NkGz
U937-A/E-9/14/18  M3\6VGFxd3C2b4Ppd{BCe3OjeR?= M1[xTFAvODFxMD6xM|EwOTBizszN NWPKSHhPPDhiaB?= NU\SbIZ6cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmjINlQ{ODB2NU[=
HT29 NIjWPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvCNYs4OiCq NXfNdGRNUUN3ME2xOFAxyrFzN{mg{txO Ml3tNlQyPzJyNkG=
SW48 NU\kVpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vX[lczKGh? Mlz4TWM2OD1zNT6yxtE3NjJizszN MWWyOFE4OjB4MR?=
HCT116 NU\mUYZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3aO|IhcA>? M4ryVWlEPTB;MT63xtExNjRizszN M4PycVI1OTd{ME[x
HepG2 NWXQcIN7TnWwY4Tpc44hSXO|YYm= NIjhNFAxNjVxMTFOwG0> NIrMO|gzPCCq NEHIWJhFVVOR Mlv2eZAuemWpdXzheIVlKHSqZTDy[YxifGm4ZTDPR3RPOiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NF3YUVMzPDF2Nki3OC=>
LS174T MorJSpVv[3Srb36gRZN{[Xl? MWWwMlUwOSEQvF2= MVqyOEBp NEW2eoNFVVOR NYTnVVEzdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> NIPZR3IzPDF2Nki3OC=>
HepG2 MWLBdI9xfG:|aYOgRZN{[Xl? M1OzPFEwOTBxMUCwJO69VQ>? NH3TZ|c4KGR? MmPQSG1UVw>? NYPrPXljcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUXweo02OjRzNE[4O|Q>
LS174T Mne1RZBweHSxc3nzJGF{e2G7 MYmxM|ExNzFyMDFOwG0> MX63JIQ> MULEUXNQ MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1\i[|I1OTR4OEe0
QBC-939 Mo\URZBweHSxc3nzJGF{e2G7 NFm4NnAyNzFyL{GwNEDPxE1? NH\hTms4KGR? M2nBZmROW09? NEH1RlVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmDMNlQyPDZ6N{S=
U251 MYLBdI9xfG:|aYOgRZN{[Xl? MlLoNU8yOC9zMECg{txO M{e4Nlch\A>? NVHnRoVLTE2VTx?= M1rIPYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4TYfVI1OTR4OEe0
HL-60 NF;xNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT0WYplOSEQvF2= MoXSOFghcA>? MWDpcoNz\WG|ZYOgS|IueGijc3WgZ4VtdCCocnHjeIlwdg>? Ml;oNlQxODB|MkS=
MDA‑MB‑453 M{i3NGZ2dmO2aX;uJGF{e2G7 NXzoOGxsOC5{L{Gg{txO MXG3NkBp NXPLSldy[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NVrtNYVLOjN6NESyNlg>
HCC1569 MnTYSpVv[3Srb36gRZN{[Xl? NG\YeYkxNjJxMTFOwG0> MXG3NkBp MUfjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= Ml\XNlM5PDR{Mki=
BT‑474 MXHGeY5kfGmxbjDBd5NigQ>? MYmwMlIwOSEQvF2= NFmzNIQ4OiCq MoLuZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NH3wZ2gzOzh2NEKyPC=>
AGS NHTCbJRCeG:ydH;zbZMhSXO|YYm= MoTsOU8yOC9{MD:1NEDPxE1? MYK0POKhcMLi MUDEUXNQ M1ThTYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh M2XnO|I{PTh{N{i0
A549 MnXqRZBweHSxc3nzJGF{e2G7 M3vjSlUwOTBxMkCvOVAh|ryP MXK0POKhcMLi NYPYdI9pTE2VTx?= M{HBe4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NYCzRodTOjN3OEK3PFQ>
AGS  NFjJNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\UOU8yOC9{MD:1NEDPxE1? NV3H[lJDPDkEoHlCpC=> MoPZSG1UVw>? MVzpcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= NUCxcHRUOjN3OEK3PFQ>
Kasumi-1 NHG3fGhCeG:ydH;zbZMhSXO|YYm= Mn;3NE42KM7:TR?= Mmq0OFjDqGkEoB?= MlH2[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= M3ezXVI{PDl|M{S4
OCI-AML3 Ml[wRZBweHSxc3nzJGF{e2G7 NVLD[YJSOi53IN88US=> MkPQOFjDqGkEoB?= NIi0fIdl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MXqyN|Q6OzN2OB?=
MV4-11 NWLIRYRjSXCxcITvd4l{KEG|c3H5 M3TydVIvPSEQvF2= NEPOdlA1QMLiaNMg NYXRSlVp\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NELYRoIzOzR7M{O0PC=>
NK  MXTDfZRwfG:6aYT5JGF{e2G7 NHT1T48xNjB{LUKwJO69VQ>? M3TkN|Uh\A>? M1XlWoRm[3KnYYPld{B1cGViY4n0c4x6fGmlIHHjeIl3cXS7IH;mJG5MKGOnbHzzJIF1KGmwdHXycYVlcWG2ZTDjc45k\W62cnH0bY9veyC{ZYP1cJRqdmdiaX6gZUBWNXOqYYDl[EBld3On4pETdoV{eG:wc3WgZ5VzfmV? MXmyN|MzQDB6OB?=
NK  NVPBcI1lSXCxcITvd4l{KEG|c3H5 M4n1T|AvODJvMkCg{txO M4DOWlUh\A>? NX\RR3oy\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm NWDrPFl3OjN|MkiwPFg>
NK  MorySpVv[3Srb36gRZN{[Xl? MXuwMlAyNTJyIN88US=> MXi1JIQ> MUnjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl MV:yN|MzQDB6OB?=
MOLT4/DNR MWnGeY5kfGmxbjDBd5NigQ>? Ml23OUDPxE1? Mmn2OEBl MnvadoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> MWKyN|A3ODV5MB?=
Jurkat/DOX NXntZpc5TnWwY4Tpc44hSXO|YYm= MXu1JO69VQ>? NHWyV|A1KGR? NF:5PYxz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? Mm\RNlMxPjB3N{C=
MOLT4/DNR NVX6ZZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV61JO69VQ>? MnT4OEBl M1y2XZJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= NVi5e2N5OjNyNkC1O|A>
Jurkat/DOX MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTFdIpxPSEQvF2= MU[0JIQ> NFPkeotz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 MmHyNlMxPjB3N{C=
ccRCC  NIjsS2NCeG:ydH;zbZMhSXO|YYm= NIjSU5MxNjBzLUGw{txO MWS3NkBp NWrySnVlTE2VTx?= M13SSIhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? M2LIb|IzQDJ4NE[3
TNBC  MWrBdI9xfG:|aYOgRZN{[Xl? MXSwMlAyNTFyzszN MX23NkBp MYnEUXNQ NI\keY5p[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w NHTLRlkzOjh{NkS2Oy=>
A498 M3;5OWFxd3C2b4Ppd{BCe3OjeR?= MWewMlAyNTFyzszN Ml;LO|IhcA>? MVfEUXNQ MYTpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NF3SV4szOjh{NkS2Oy=>
KIJ265T NFHKTIZCeG:ydH;zbZMhSXO|YYm= NWLRfXc3OC5yMT2xNO69VQ>? NGPxS204OiCq MkDxSG1UVw>? MnTHbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NF7JWlQzOjh{NkS2Oy=>
MDA-231 MWPBdI9xfG:|aYOgRZN{[Xl? MmmwNE4xOS1zMN88US=> NIL0ZWM4OiCq NU[5PIJrTE2VTx?= MlLkbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NYnJWGl3OjJ6Mk[0Olc>
BT-20 MV7BdI9xfG:|aYOgRZN{[Xl? NIe4fWsxNjBzLUGw{txO M3fjU|czKGh? M4rXXGROW09? M2jKSIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MlrsNlI5OjZ2Nke=
U937 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVq1MVIxKM7:TR?= MWKyOE81QC95MjDo MnvUbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MW[yNlc3PzB{MR?=
HL60 MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVG1MVIxKM7:TR?= NVy0WVJtOjRxNEivO|IhcA>? MXPpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NXvsTlFLOjJ5NkewNlE>
U937 M{\zfmFxd3C2b4Ppd{BCe3OjeR?= NIfndmcyPSEQvF2= MnT6NlQwPDhxN{KgbC=> MVPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NUmxTFIxOjJ5NkewNlE>
HL60 NYP3ZXM2SXCxcITvd4l{KEG|c3H5 MXyxOUDPxE1? MYKyOE81QC95MjDo NWPxOXNPcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NEO4S|AzOjd4N{CyNS=>
LS411N  MlyzRZBweHSxc3nzJGF{e2G7 MXGwMlUh|ryP NXzXZo9FPzJiaB?= MlrnbY5kemWjc3XzJGZieyCvUl7BJIxmfmWu MoqzNlI1PjF4OUW=
MDA-MB-231 NVLESnZzSXCxcITvd4l{KEG|c3H5 MV6xNEDPxE1? Ml7LOFghcA>? NHzPVJNz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NF;pOIYzOTh6N{[5Oy=>
MCF-7  MYjBdI9xfG:|aYOgRZN{[Xl? NYLuVHI2OTBizszN MkmwOFghcA>? M3TvOZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWPkUWtyOjF6OEe2PVc>
A375 M3zzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu2NE42KM7:TR?= MlXONU82NzhiZB?= MkHqbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M4jjVlIyPzl4NkKy
SKMEL1 M3vDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHTPHkxNjVizszN NHO5[lkyNzVxODDk NIHP[pNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NFHr[HozOTd7Nk[yNi=>
SKMEL3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7heYJbOC53IN88US=> NHnlNIcyNzVxODDk NYnMb3dGcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NFnHXHAzOTd7Nk[yNi=>
SKMEL28 M3vGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXiwMlUh|ryP NW[yUJNKOS93L{ig[C=> MlvjbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MYSyNVc6PjZ{Mh?=
MeWo NFPkc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3racFAvPSEQvF2= MYixM|UwQCCm NUf4R|BmcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NETDUpkzOTd7Nk[yNi=>
B16 NILGO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTvNE42KM7:TR?= MUKxM|UwQCCm NVe2WI5HcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MmTiNlE4QTZ4MkK=
Ly 1 MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XHflI1KGh? MW\JR|UxRTdwMzFOwG0> NX7iVmk6OjF5N{KwOFk>
Ly 7 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki1NlQhcA>? MkmwTWM2OD1zMD63JO69VQ>? MnX4NlE4PzJyNEm=
Su-DHL6 NHq3U2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3MdoUzPCCq NXH1OVlWUUN3MP-8olIxKM7:TR?= NEnJbVMzOTd5MkC0PS=>
Ly 10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjpbXEzPCCq MlraTWM2OO,:nkKwJO69VQ>? NEf5SokzOTd5MkC0PS=>
RIVA NVXofYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe0T2REOjRiaB?= M1PJV2lEPTExvK6yNEDPxE1? MX:yNVc4OjB2OR?=
Su-DHL2 NFW3NIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXSwdpI1OjRiaB?= NIrHT2dKSzVy78{eNlAh|ryP MX2yNVc4OjB2OR?=
Ly 1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYG0PEBp NIDOSlFKSzVyPUCuN|Qh|ryP NFPmWWQzOTd5MkC0PS=>
Ly 7 NXjnSI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYm0PEBp M1v1R2lEPTB;MD6wNlUh|ryP NIPO[VEzOTd5MkC0PS=>
Su-DHL6 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX5cYM1QCCq M2LwfWlEPTExvK6yNEDPxE1? NIjwUZUzOTd5MkC0PS=>
Ly 10 NICzWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjtU4FQPDhiaB?= M4LseGlEPTB;MT64JO69VQ>? MU[yNVc4OjB2OR?=
RIVA MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\LOFghcA>? NGXjO3JKSzVy78{eNlAh|ryP NE\yXZczOTd5MkC0PS=>
Su-DHL2 NFSzS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS4NYI1QCCq NHv0Z2tKSzVyPUG3MlQh|ryP NXntUo9XOjF5N{KwOFk>
Ly 1 MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rMdlczKGh? NVzz[mRYUUN3ME2wMlAyKM7:TR?= NU\NWYV{OjF5N{KwOFk>
Ly 7 NXSwOVdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fVT|czKGh? M4fPOmlEPTB;MD6wNVgh|ryP NX\nUlQ1OjF5N{KwOFk>
Su-DHL6 MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTWO|IhcA>? M1TjPGlEPTB;MT62JO69VQ>? MYiyNVc4OjB2OR?=
Ly 10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPiXIU3PzJiaB?= NF7ybmdKSzVyPUGuNkDPxE1? MlnNNlE4PzJyNEm=
RIVA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml71O|IhcA>? NYH1U4RVUUN3MP-8olIxKM7:TR?= NX\YSXQzOjF5N{KwOFk>
Su-DHL2 M{fWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX5eWdzPzJiaB?= MXfJR|UxRTFzLkKg{txO MXOyNVc4OjB2OR?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferase信号経路図

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID